January 3, 2013 | by Phil Reese
Price of new once-daily AIDS drug draws criticism
Truvada, Gilead, gay news, Washington Blade

(Photo courtesy of Gilead)

SAN FRANCISCO — Gilead’s new once-daily AIDS drug Stribild provides an attractive option for those with HIV who have never started a meds regiment before, but activists say the $33,000 a year price-tag will make it unattainable for most who need it.

“In the long run, the cost to Gilead to actually produce [Stribild] will be a small fraction of its selling price, which means Gilead can show restraint on…pricing and still make an enormous profit,” AIDS Healthcare Foundation president Michael Weinstein told the Huffington Post, after a massive ACT UP San Francisco demonstration at the drug maker’s headquarters over the price.

Activists are putting pressure not just on Gilead, but on lawmakers to intervene and making HIV drugs more affordable for more people.

 

2 Comments
  • This is horrific! I can't believe the audacity of drug companies – all of which take total advantage of the fact that people desperately need these medications. Shameful!

    • That is the sad price we pay for drug companies and their desire to profit. Many of them use federal funds to do their research only to turn around and pick the pockets of those that need the drugs most. Each corporate person who pushes the high price on these types of drugs should realize their actions will haunt not only the world but their souls.

© Copyright Brown, Naff, Pitts Omnimedia, Inc. 2014. All rights reserved.
Directory powered by Business Directory Plugin